Steady State Pharmacokinetics of Naproxen in Elderly Rheumatics Compared with Young Volunteers
Overview
Authors
Affiliations
The elderly rheumatic patients and 7 healthy young persons received naproxen (Naprosyn, Syntex) 500 mg orally twice a day for 4 weeks. The serum concentrations were determined using mass fragmentography. After an initial 1,000-mg dose, no significant differences were found between the two groups in peak serum concentration, time to peak serum concentration, area below the serum concentration-time curve, volume of distribution, elimination half-life, or total body clearance of naproxen. At steady state, the median total through naproxen concentration was 50.5 mg/l in the elderly and 62.7 in the young (p = 0.08); the unbound concentration was 58 micrograms/l and 44 micrograms/l, respectively (p = 0.06). There was a significant inverse correlation between serum albumin and the free fraction of naproxen (R = -0.58, p = 0.01). The hepatic extraction ratio of naproxen is relatively low and it is suggested that the reduced protein binding in the elderly may conceal the age-related reduction in cellular activity. An estimated value of intrinsic clearance was reduced by 37% in the elderly patients. It is suggested to start naproxen at the lower end of its dose range in the elderly.
The 'apparent clearance' of free phenytoin in elderly vs. younger adults.
Wright D, Begg E Br J Clin Pharmacol. 2010; 70(1):132-8.
PMID: 20642556 PMC: 2909816. DOI: 10.1111/j.1365-2125.2010.03673.x.
Free drug metabolic clearance in elderly people.
Butler J, Begg E Clin Pharmacokinet. 2008; 47(5):297-321.
PMID: 18399712 DOI: 10.2165/00003088-200847050-00002.
Clinical pharmacokinetics of naproxen.
Davies N, Anderson K Clin Pharmacokinet. 1997; 32(4):268-93.
PMID: 9113437 DOI: 10.2165/00003088-199732040-00002.
Todd P, Clissold S Drugs. 1990; 40(1):91-137.
PMID: 2202585 DOI: 10.2165/00003495-199040010-00006.